announcement

PHILADELPHIA —Susan J. Mandel, MD, MPH, director of Clinical Endocrinology and Diabetes for the University of Pennsylvania Health System, and a professor in the division of Diabetes, Endocrinology and Metabolism in Penn’s Perelman School of Medicine, has been elected President-elect of the Endocrine Society. Mandel will officially begin her term in April 2017 and will take office as President in 2018.

The Endocrine Society is the largest global membership organization representing professionals from the field of endocrinology including medical doctors, scientists, researchers, and educators. Its mission is to advance excellence in endocrinology and promote its essential and integrative role in scientific discovery, medical practice, and human health.

“Having worked with Susan for nearly 20 years here at Penn, I have seen firsthand her leadership, commitment to education, and clinical and research expertise,” said Mitchell A. Lazar, MD, PhD, chief of the division of Endocrinology, Diabetes and Metabolism. “Susan has delivered first-class care to her patients year after year, and is well-established as an international expert in the diagnosis, evaluation and treatment of thyroid nodules and thyroid cancer.  She has also been an innovative leader of Penn's training program for Fellows in Endocrinology and Metabolism."

In addition, Mandel is director of the Fellowship Program in the division of Endocrinology, Diabetes, and Metabolism where she is overseas and educates upwards of 8 clinical and research fellows each year. Mandel serves as associate chief of the Division of Endocrinology, Diabetes, and Metabolism and she is director—and the creator—of the Thyroid Nodule Clinic at Penn Medicine, which was the second in the country to be established and the first of its kind in the tri-state area. Over the course of her nearly 30 year career, Mandel established the model for thyroid nodule evaluative services and she was one of the first endocrinologists to teach neck ultrasound to endocrine practitioners.

Mandel’s clinical and research interests include the use of sonography in the evaluation of patients with thyroid nodules, the novel introduction of I-123 imaging in differentiated thyroid cancer, and thyroid disease during pregnancy. She has also been on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and Thyroid. Among her involvement in the Endocrine Society, Mandel is also currently involved with the American Association of Clinical Endocrinologist, American Thyroid Association, Association of Program Directors in Endocrinology and Metabolism, Women in Endocrinology and the American Board of Internal Medicine. Most notably, Mandel has served on the taskforces that have written the ATA guidelines for the management of patients with thyroid nodules and thyroid cancer, as well as the management of thyroid disorders during pregnancy.   

Joining the faculty in the Perelman School of Medicine at the University of Pennsylvania as an assistant professor of Medicine in 1997, Mandel then became an associate professor of Medicine, and finally a professor of Medicine in 2008. Mandel received her bachelor of arts degree from Harvard University, her medical degree from the Columbia University College of Physicians and Surgeons, and her master’s in public health at the Harvard School of Public Health. She began her career as an intern then resident at Columbia Presbyterian Medical Center and she completed a clinical fellowship at Brigham and Women's Hospital and a research fellowship at Harvard Medical School, where she serves as an instructor of Medicine for five years.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: